Todd C. Brady - Mar 9, 2024 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Role
President and CEO, Director
Signature
/s/ Todd C. Brady
Stock symbol
ALDX
Transactions as of
Mar 9, 2024
Transactions value $
-$580,760
Form type
4
Date filed
3/12/2024, 08:01 PM
Previous filing
Sep 11, 2023
Next filing
May 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALDX Common Stock Sale -$321K -97.9K -5.92% $3.27 1.56M Mar 11, 2024 Direct F1, F2
transaction ALDX Common Stock Sale -$260K -85.3K -5.48% $3.05 1.47M Mar 12, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALDX Stock Option (right to buy) Award $0 +1.08M $0.00 1.08M Mar 9, 2024 Common Stock 1.08M $3.62 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.35. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.11. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024.